Abstract: Compounds of the formula: ##STR1## wherein A is ##STR2## R is mono- or dihalo, amino, nitro, cyano, hydroxy, trifluoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, lower cycloalkyl, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkanoylamino, lower alkyl thio, loweralkyl-sulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro;X and Y are each, independently, hydrogen or ##STR3## wherein R.sup.1 is hydrogen or lower alkyl;R.sup.2 is hydrogen or lower alkyl; orR.sup.1 and R.sup.2 taken together form a heterocyclic moiety selected from 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-octahydroazocinyl, 3-thiazolidinyl, 4-morpholinyl or 4-thiomorpholinyl, with the proviso that one of X and Y is always hydrogen;n is 1-4;and the pharmacologically acceptable salts thereof, which are intermediates in preparing H.sub.

Abstract: Compounds of the formula: ##STR1## wherein B is a moiety having the formula: ##STR2## R is mono- or dihalo, amino, nitro, cyano, hydroxy, trifluoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, cycloalkyl of 4-7 carbon atoms, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkanoylamino, lower alkyl thio, lower alkylsulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro.X is SO.sub.2, SO, S or C.dbd.O; andA is amine selected from the group ##STR3## , wherein R.sup.1 is hydrogen or R.sup.2 CH.sub.2 wherein R.sup.2 is mono- or diloweralkylamino, mono- or di-N-lower alkylaminoloweralkyl, (2-furyl)methylamino, benzylamino, lowercycloalkylamino, 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-octahydroazocinyl, 3-thiazolidinyl, 4-morpholinyl or 4-thiomorpholinyl; R.sup.3 is hydrogen or (1-piperidinyl)methyl with the proviso that when R.sup.

Abstract: Compounds of the formula: ##STR1## wherein X is SO.sub.2, SO or S; andA is an amine selected from the group: ##STR2## wherein R is hydrogen, (lower)alkyl, (lower)alkoxy or halo; n is 2-4; andthe pharmacologically acceptable salts thereof are disclosed.

Abstract: Prostaglandin compounds substituted at the 11-position, and possessing bronchodilating and hypotensive activity are prepared from PGA.sub.2 and its esters and 15-epimers.

Abstract: Prostaglandin compounds substituted at the 11-position, and possessing broncho-dilating and hypotensive activity are prepared from PGA.sub.2 and its esters and 15-epimers.

Abstract: Prostaglandin compounds substituted at the 11-position, and possessing bronchodilating and hypotensive activity are prepared from PGA.sub.2 and its esters and 15-epimers.

Abstract: 9-Oxo-15-Substituted prostanoic acids, and intermediates for their preparation are disclosed. The final products have bronchodilatory activity.

Abstract: Processes for the total synthesis of dl-11-deoxy-15-substituted prostaglandins, novel intermediates therefore, certain novel final products, as well as optical resolutions of the final products are disclosed.The final products are bronchodilators.

Abstract: Prostaglandin compounds substituted at the 11-position, and possessing broncho-dilating and hypotensive activity are prepared from PGA.sub.2 and its esters and 15-epimers.

Abstract: Prostaglandin compounds substituted at the 11-position, and possessing bronchodilating and hypotensive activity are prepared from PGA.sub.2 and its esters and 15-epimers.

Abstract: 9-Oxo-15-substituted prostanoic acids, and intermediates for their preparation and for the preparation of other known prostaglandins are disclosed. The final products have bronchodilatory activity.

Abstract: Prostaglandin compounds substituted at the 11-position with a methyl group are prepared from PGA.sub.2, its 15-epimer, and their esters. These compounds, not heretofore found in nature, possess a variety of pharmacological activities one of which is bronchodilation.

Abstract: Derivatives of 11-deoxy-PGE.sub.1 and 11-deoxy-PGE.sub.2 are prepared. These new compounds not heretofore found in nature possess various pharmacological activities, one of which is bronchodilation.

Abstract: Prostaglandin compounds substituted at the 11-position, and possessing bronchodilating and hypotensive activity are prepared from PGA.sub.2 and its esters and 15-epimers.

Abstract: 11-Deoxy-prostaglandin compounds having a lower alkyl group at position-15 are prepared from PGA.sub.2 esters and 15-epimers. These 15-lower alkyl-11-deoxy prostaglandins possess bronchodilative ability.

Abstract: Derivatives of 11-deoxy-PGE.sub.2 are prepared. These new compounds not heretofore found in nature possess various pharmacological activities, one of which is the inhibition of gastric secretion.

Abstract: Processes for the total synthesis of dl-11-deoxy-15-substituted prostaglandins, novel intermediates therefore, certain novel final products, as well as optical resolutions of the final products are disclosed.The final products are bronchodilators.

Abstract: The topical application of 7-(5.alpha.-hydroxy-2.beta.-[(3RS)-3-hydroxy-3-methyl-trans-1-octenyl]-3.a lpha.-methyl-1.alpha.-cyclopentyl)-cis-5-heptenoic acid, 7-(5.alpha.-hydroxy-2.beta.-[(3RS)-3-hydroxy-3-methyl-trans-1-octenyl]-1.a lpha.-cyclopentyl)-cis-5-heptenoic acid, or 7-(2.beta.-[(3RS)-hydroxy-3-methyl-trans-1-octenyl]-5-oxo-1.alpha.-cyclope ntyl)-cis-5-heptenoic acid to a wound surface can be employed to attenuate bleeding. The compounds are prepared from the prostaglandin PGA.sub.2.

Abstract: 11.alpha.-Cyano-15-substituted PGE.sub.1 analogs, related compounds and intermediates thereto are disclosed. The final products have bronchodilatory, or anti-inflammatory activity.

Abstract: 11-Deoxy-prostaglandin compounds having a lower alkyl group at position-15 are prepared from PGA.sub.2 esters and 15-epimers. These 15-lower alkyl-11-deoxy prostaglandins possess bronchodilative ability.